EyeYon Medical Ltd
- Home
- Companies
- EyeYon Medical Ltd
- News
- EyeYon Medical’s Q3/20 Newsletter
EyeYon Medical’s Q3/20 Newsletter
Sep. 1, 2020
Courtesy ofEyeYon Medical Ltd
Vision accessibility for anyone, anywhere
Ready for use, Artificial Endothelial Layer EndoArt® aims to eliminate the need for donor tissue in corneal edema treatment.
All you wanted to know about the disruptive EndoArt® Artificial Endothelial Layer at one publication!
Take a look at this exciting article with the latest, most updated results of our First in Human trial, already recruited 15 patients with a follow-up of 15 months, demonstrating safety & efficacy and benefiting the lives of our patients.
There are also some important insights from leaders in Ophthalmology: Dr. Ruth Lapid-Gurtzak and Prof. Gerd Auffarth.
All you wanted to know about the disruptive EndoArt® Artificial Endothelial Layer at one publication!
Take a look at this exciting article with the latest, most updated results of our First in Human trial, already recruited 15 patients with a follow-up of 15 months, demonstrating safety & efficacy and benefiting the lives of our patients.
There are also some important insights from leaders in Ophthalmology: Dr. Ruth Lapid-Gurtzak and Prof. Gerd Auffarth.
ASCRS2020 Film Festival Winner: CSI Heidelberg: DMEK with Artificial Implant Instead of Human Tissue
We are so proud to share that our successful results of the Hyper-CL™ therapeutic contact lens, comparative study, treating corneal edema, are published now at the Journal of Ophthalmology!
Corneal edema was just the first proven indication using the drug depot capabilities of the Hyper-CL™, followed by many other such as infection, inflammation, dry eye, and more.